



Oscillating Positive
Expiratory Pressure Therapy System

Empowering COPD Patients

To Breathe Better, Live Better
by Reducing Exacerbations⁶


77% of COPD patients have experienced an exacerbation[†] increasing risk of hospitalization and driving disease progression.¹



Globally COPD is...



4th leading cause of death²



More than **251 million** cases³



More than **3 million** death³

The **Countdown** to her **next COPD exacerbation** has **already begun**



Acute exacerbations result in:

- ***Decline*** in lung function⁵
- ***Poorer quality*** of life⁵
- ***Increased*** mortality⁵
- ***Frequent*** hospital admissions, relapses and readmissions⁵

1 in 5 patients **hospitalized for a COPD exacerbation** require **rehospitalization within 30 days**⁶



Oscillating Positive
Expiratory Pressure Therapy System


The **Aerobika[®]** device works to address the structural and functional challenges in the airways of patients with COPD.

In a real-world study with COPD patients with chronic bronchitis, the **Aerobika[®]** device was clinically proven to reduce exacerbations, and is **clinically proven to reduce exacerbations, increase lung function and improve patient quality of life.**⁶



How the **Aerobika[®]** Oscillating Positive Expiratory Pressure (OPEP) device works


Designed to address the structural and functional challenges in post-exacerbation airways



Mucus clearance can reduce breathlessness, prevent recurring infection, reduce exacerbations, hospitalizations and improve quality of life.⁸




Reduces COPD exacerbations by 28% in the critical 30 day period⁶



Real world study measured the rate of early (30-day) moderate-to-severe exacerbations and related costs in COPD patients with chronic bronchitis. Moderate-to-severe exacerbation is defined as a hospitalization or an emergency department visit.

Improves Quality of Life in COPD Patients⁹

Responder rate analysis for improvements greater than the Minimum Clinically Important Difference (MCID)



[†] Randomized cross-over study evaluating four-times daily Aerobika® device use after 3-4 weeks of treatment in COPD patients with chronic bronchitis.


[‡] Clinical assessment of COPD patients with chronic bronchitis over 8 weeks of treatment with the Aerobika® OPEP device.

St. George's Respiratory Questionnaire (SGRQ) measures impact on overall health, daily life and perceived well-being in airways disease; MCID ≥ 4
COPD Assessment Test (CAT) assesses impact of COPD on health status; MCID ≥ 2

Improves Ventilation in COPD Patients⁸

Before
Baseline care (no OPEP/PEP device)


After
Baseline care plus **Aerobika*** device



Teal colour and intensity show areas with gas distribution. Yellow circles represent areas of greatest change after 3-4 weeks of **Aerobika*** device use.

Randomized cross-over study evaluating four-times daily **Aerobika*** device use after 3-4 weeks of treatment in patients with COPD and chronic bronchitis. Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) ventilation in representative sputum producer.


Improves Lung Function in COPD Patients⁸



Randomized cross-over study evaluating four-times daily **Aerobika*** device use after 3-4 weeks of treatment in COPD patients with chronic bronchitis. FVC=forced vital capacity

Efficiency and Effectiveness¹⁰

- ✓ Oscillations occur from the start through to the end of the breath
- ✓ The amplitude of the oscillations is high and consistent
- ✓ Frequency of the oscillations mimics natural airway cilia movement



Adapted from Meyer and Suggett, poster presented at CHEST 2017.⁶



Percentage of exhaled breath with oscillations

81% Aerobika* device

67% Acapella Choice†

62% Flutter†

Average oscillation pressure amplitude (cm H₂O)

13.9 Aerobika* device

5.8 Acapella Choice†

3.0 Flutter†


The **Aerobika*** OPEP device was the most efficient and effective OPEP device tested *in vitro*¹⁰

Aerobika* OPEP Device compared to Acapella¹¹


Real world evidence among Chronic Obstructive Pulmonary Disease (COPD) patients with chronic bronchitis on Hospital Readmissions at 30 Days and 12 Months

n = 619 Aerobika* OPEP Device n = 1857 Acapella


30 Days Results



12 Month Results




COPD Patients Feedback Survey




How to Use



1 CLOSE LIPS
around mouthpiece



2 INHALE and HOLD
2-3 seconds



3 EXHALE—slowly,
steady, firmly



4 REPEAT and
huff cough

Administer for 10 minutes, twice daily.


How to Clean



1 WASH
in soapy water



2 RINSE
in clean water



3 AIR DRY
thoroughly



DISHWASHER SAFE
top rack in basket



Drug-free

- Handheld mechanical device designed to address the structural and functional challenges in the airways of patients with COPD

Clinically Proven

- **Reduces** exacerbations⁶
- **Improves** lung ventilation and function⁶
- **Improves** patient quality of life⁶

Easy to Use

- Disassembles into 4 parts for ease of cleaning and disinfection
- Position independent
- Inhale and exhale without removing from mouth
- Adjustable resistance settings
- Oscillations are maintained from the start to the end of each breath



Prescribe the **Aerobika^{*}** device as an add-on to **usual COPD treatment**.
Available behind the counter at retail pharmacy.

Prescription coverage is easy. Pay and Submit.

1. Neil Barnes et al; COPD and exacerbations: Patient insights. BMC Pulmonary Medicine 2013. 2. O'Donnell E Dennis et al; Canadian Thoracic society reco.for the management of COPD. Can Respir J 2008;15 3. All causes readmission to acute care. Canadian institute of health informatics ISBN 978-1-77109-040-7,2012. 4. <https://www.lungsask.ca/about-us/news-room/backgrounders-and-information-sheets/copd-fact-sheet> last accessed on 14/7/2020. 5. Bourbeau et al; CTS position statement: Pharmacotherapy in patients with COPD. Canadian J. of resp, cric. Care and sleep medicine 2017 vol.1. 6. Burudpakee et al; Pulm Ther 2017 DOI: 10.1007/s41030-017-0027-5 7. Glenn Leemans et al; COPD Functional resp.imaging. International J. of COPD 2020. 8. Svenningsen S. et al. Oscillatory Positive Expiratory Pressure in Chronic Obstructive Pulmonary Disease. COPD 2016;13(1):66-74. 9. Suggett J; QoL responder rate analysis; SGRO vs CAT assessment. COPD 10, 2016 UK. 10. Meyers et al; A lab assessment of different OPEP device. CHEST 2017. 11. J. Suggett et al; A retrospective cohort study comparing 2 OPEP devices in patients with COPD. ATS 2020. 12. Harkness H. et al; Survey of Patients Using an OPEP device. Canadian respiratory conf. 2015.



**TRUDELL MEDICAL
INTERNATIONAL**

MD-061A-0720 *trade-marks of Trudell Medical International (TMI).
† trade-marks of the respective companies. © TMI 2020. All rights reserved.
Manufactured in Canada with Canadian and USA Parts.



Scan to watch
how to use
and how to clean

저희 부스에 방문해 주시고 자료를 검토해 주셔서 감사드립니다.

저희 맥진 메디칼은 본 Aerobika 객담배출 유도기에 대해 관심을 가지시고 추가 정보를 원하시는 의사 선생님들께 관련 논문이나 샘플 등을 제공해 드릴 예정입니다.

추가 정보를 원하실 경우 아래 연락처를 이용해 연락 주시기 바랍니다.

감사합니다.



TEL : 1577-3488, E-mail : chr@macjin.com,
Homepage : www.macjinmedical.com